Last reviewed · How we verify
Losartan Tablets
Losartan blocks angiotensin II receptors on blood vessels and tissues, causing vasodilation and reducing blood pressure.
Losartan blocks angiotensin II receptors on blood vessels and tissues, causing vasodilation and reducing blood pressure. Used for Hypertension, Diabetic nephropathy in patients with type 2 diabetes, Heart failure with reduced ejection fraction.
At a glance
| Generic name | Losartan Tablets |
|---|---|
| Sponsor | Istituto Auxologico Italiano |
| Drug class | Angiotensin II receptor antagonist (ARB) |
| Target | AT1 receptor (angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Losartan is an angiotensin II receptor antagonist (ARB) that selectively blocks the AT1 receptor subtype. By preventing angiotensin II from binding to these receptors, it inhibits vasoconstriction and aldosterone secretion, leading to reduced peripheral vascular resistance and lower blood pressure. This mechanism also provides renal protection and reduces left ventricular hypertrophy.
Approved indications
- Hypertension
- Diabetic nephropathy in patients with type 2 diabetes
- Heart failure with reduced ejection fraction
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia
- Cough
- Headache
- Hypotension
Key clinical trials
- The Effect of Losartan on Cephalexin (PHASE1)
- Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease (PHASE2)
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Losartan + Sunitinib in Treatment of Osteosarcoma (PHASE1)
- Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction (PHASE4)
- Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer (PHASE2)
- Exploration of Postoperative Adjuvant Therapy for HCC Patients With Positive TB (PHASE4)
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |